Defence Therapeutics Launches Convertible Debenture Offering

Defence Therapeutics (TSE:DTC) has released an update.

Defence Therapeutics, a Canadian biopharmaceutical firm, has announced the offering of new unsecured convertible debentures aimed at raising up to CAD$1,570,000. These debentures, offering an 8% interest rate, are convertible into common shares, potentially resulting in the issuance of over 2.6 million shares. This financial move is part of the company’s strategy to settle outstanding debt while continuing to advance its innovative biopharmaceutical technologies.

For further insights into TSE:DTC stock, check out TipRanks’ Stock Analysis page.